NanoMedSyn will participate to the International Symposium on Inorganic and Environmental Materials ISIEM2023 in Montpellier, France. The symposium will focus on the newest research and technologies on inorganic materials : Nanomaterials, Biomaterials, Functional Materials… https://isiem2023.sciencesconf.org
The 3rd Immune-Oncology World Congress Immuno-Oncology2022 will focus on the latest developments and findings in immuno-oncology therapy as well as targeted therapy. The Congress will examine treatments available on the market as well as treatments still in the development stage. A poster of our work will be on display for the duration of the Congress.
Invest in Biomed, 7th edition. For innovative companies with high potential in healthtech, Eurobiomed continues its support.
Day of the cluster : Biotherapy Innovation Occitanie October 13, 2022 in Montpellier https://www.agence-adocc.com/biotherapie-innovation-occitanie/
NanoMedSyn is co-organiser of the 2nd Symposium on delivery and target for pediatric tumors, on 23-24th June in Switzerland (Schwarzsee). Our collaborative work and of the company have been presented.
10th Antibody Industrial Symposium 2022 We are proud to announce our participation to the 10th Antibody Industrial Symposium 2022 (AIS2022) that will be held from 28th to 29th June 2022 in person in Montpellier, France. https://aiscongress.com
Henry-Vincent Charbonné (1953-2021)
NanoMedSyn is classified as a DEEPTECH company by Bpifrance for its Innovative Therapeutic Targeting Technology.
NanoMedSyn has signed a research agreement with the French National Research Agency within the framework of the « Plan France Relance Préservation de l’Emploi de R&D ». This agreement concerns a two-year collaborative research project with a CNRS institute in Montpellier, the Max Mousseron Institute of Biomolecules.
NanoMedSyn has been distinguished for its Growth Path by Bpifrance and joins the « Excellence » community.